Jo PalmerPhillips - Climb Bio Chief Officer
| CLYM Stock | 1.70 0.25 17.24% |
Executive
Jo PalmerPhillips is Chief Officer of Climb Bio
| Address | 20 William Street, Wellesley Hills, MA, United States, 02481 |
| Phone | 866 857 2596 |
| Web | https://climbbio.com |
Climb Bio Management Efficiency
The company has return on total asset (ROA) of (0.1895) % which means that it has lost $0.1895 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6204) %, meaning that it created substantial loss on money invested by shareholders. Climb Bio's management efficiency ratios could be used to measure how well Climb Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of August 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Climb Bio's Non Current Assets Total are very stable compared to the past year. As of the 4th of August 2025, Non Currrent Assets Other is likely to grow to about 423.1 K, while Other Current Assets are likely to drop about 2.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thien Ho | Dine Brands Global | N/A | |
| Lars Moravy | Tesla Inc | N/A | |
| Thierry Chaumont | BCE Inc | N/A | |
| Laura Franco | Sphere Entertainment Co | 62 | |
| Hadeer Hassaan | BCE Inc | N/A | |
| Jeffrey Straubel | Tesla Inc | 48 | |
| Peter Bannon | Tesla Inc | N/A | |
| Bin Sun | Zhihu Inc ADR | 43 | |
| Travis Axelrod | Tesla Inc | N/A | |
| Ray Casazza | Sphere Entertainment Co | N/A | |
| Wang Han | Zhihu Inc ADR | N/A | |
| CBE CEng | Sphere Entertainment Co | 56 | |
| Turner Caldwell | Tesla Inc | N/A | |
| Richard Constable | Sphere Entertainment Co | N/A | |
| Susan Nelson | Dine Brands Global | N/A | |
| Sarah CannonFoster | Dine Brands Global | N/A | |
| Charles Scaccia | Dine Brands Global | N/A | |
| Han Wang | Zhihu Inc ADR | 33 | |
| Ari CFA | Sphere Entertainment Co | N/A | |
| Joel Fisher | Sphere Entertainment Co | N/A | |
| John Walker | Tesla Inc | 62 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 |
Climb Bio Leadership Team
Elected by the shareholders, the Climb Bio's board of directors comprises two types of representatives: Climb Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Climb. The board's role is to monitor Climb Bio's management team and ensure that shareholders' interests are well served. Climb Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Climb Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jo PalmerPhillips, Chief Officer | ||
| Chandra JD, VP Counsel | ||
| Emily CPA, Senior Officer | ||
| Cindy MBA, Senior Finance | ||
| Emily Pimblett, Chief Officer | ||
| Nishi MD, Senior Development | ||
| MD MBA, Treasurer, COO | ||
| Janaki MSc, VP Affairs | ||
| Perrin BS, Chief Officer | ||
| Kate MBA, Senior Management | ||
| BAO BCh, President CEO | ||
| William Bonificio, Interim Officer | ||
| MSc MD, Chief Officer |
Climb Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Climb Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (11.77 M) | ||||
| Shares Outstanding | 67.58 M | ||||
| Shares Owned By Insiders | 7.95 % | ||||
| Shares Owned By Institutions | 84.98 % | ||||
| Number Of Shares Shorted | 1.38 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (30.36 M) | ||||
| Net Income | (73.9 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.